EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients’ response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in EZH2 at diagnosis in tissue and ctDNA in patients with FL and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Laperche, C., Sanz-Villanueva, L., Díaz Crespo, F. J., Muñiz, P., Martín Rojas, R., Carbonell, D., Chicano, M., Suárez-González, J., Menárguez, J., Kwon, M., Diez Martín, J. L., Buño, I., Bastos Oreiro, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476261/
https://www.ncbi.nlm.nih.gov/pubmed/36104682
http://dx.doi.org/10.1186/s12885-022-10070-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476261/
https://www.ncbi.nlm.nih.gov/pubmed/36104682
http://dx.doi.org/10.1186/s12885-022-10070-z

Ejemplares similares